Biofrontera AG BIFRF
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.12% | -20.16% | 7.43% | -14.52% | 43.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.12% | -20.16% | 7.43% | -14.52% | 43.93% |
| Cost of Revenue | 33.15% | 11.92% | 51.24% | -53.27% | 42.57% |
| Gross Profit | 24.57% | -15.51% | -5.67% | 4.62% | 44.26% |
| SG&A Expenses | 16.64% | 333.07% | -23.74% | -3.27% | 12.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.10% | 171.85% | 4.44% | -36.65% | 26.51% |
| Operating Income | 104.66% | -130.62% | 4.95% | 87.23% | 97.09% |
| Income Before Tax | 120.19% | -147.58% | 57.85% | 91.91% | 115.62% |
| Income Tax Expenses | -- | -- | -- | -- | 32.53% |
| Earnings from Continuing Operations | 120.19% | -140.03% | 57.73% | 91.91% | 103.90% |
| Earnings from Discontinued Operations | 165.54% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 260.76% | -94.05% | 57.73% | 124.27% | 103.90% |
| EBIT | 104.66% | -130.62% | 4.95% | 87.23% | 97.09% |
| EBITDA | 139.69% | -130.04% | 6.24% | 90.53% | 89.48% |
| EPS Basic | 263.73% | -93.56% | 57.49% | 101.13% | 103.94% |
| Normalized Basic EPS | 120.33% | -147.77% | 57.61% | 99.62% | 115.78% |
| EPS Diluted | 263.73% | -93.48% | 57.49% | 101.13% | 103.94% |
| Normalized Diluted EPS | 120.33% | -147.77% | 57.61% | 99.62% | 115.78% |
| Average Basic Shares Outstanding | -0.85% | 0.00% | -0.64% | 2,050.59% | -0.99% |
| Average Diluted Shares Outstanding | -0.85% | 0.00% | -0.64% | 2,050.59% | -0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |